Open forum infectious diseases · 2025
Sustained Impact of Task-shifting HCV Treatment to Nonspecialist Providers: 5-Year Follow Up of the ASCEND Investigation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mollenkopf Sarah, Rosenthal Elana, Teferi Geb, Silk Rachel, George Nivya, Masur Henry, Kottilil Shyam, Kattakuzhy Sarah
Аннотация
BACKGROUND: Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) has ushered in an era of short-duration treatment with high effectiveness across varied patient populations. In the ASCEND investigation, treatment with DAA was efficacious when delivered by nonspecialist and specialist providers. However, long-term outcomes after initial treatment are unknown.
OBJECTIVE: To determine the long-term outcomes after DAA treatment independently provided by nurse practitioners, primary care physicians, or specialist physicians using DAA therapy.
DESIGN: Retrospective cohort study.
SETTING: Twelve urban, federally qualified health centers in the District of Columbia.
PARTICIPANTS: A total of 551 patients treated for HCV in the ASCEND investigation (A Phase IV Pilot Study to Assess of Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia).
INTERVENTIONS: None.
MEASUREMENTS: Sustained viral response (SVR12), reinfection, retreatment, death.
RESULTS: In this large sample of majority Black individuals receiving care at community-based centers, there was an initial 87% rate of SVR, and after 5 years of follow up, an additional 6.5% of participants were found to be cured. This included individuals originally lost to follow up whose subsequent testing confirmed SVR12, and those with successful retreatment after initial treatment failure. There was a 70% rate of testing for reinfection, with 2 identified reinfections. Treatment outcomes were not associated with original treating provider type.
LIMITATIONS: As a retrospective analysis, these findings are limited by the availability of data in the electronic medical record.
CONCLUSIONS: DAA is an effective treatment for HCV and can safely be prescribed by multiple provider types, with favorable long-term outcomes.
OBJECTIVE: To determine the long-term outcomes after DAA treatment independently provided by nurse practitioners, primary care physicians, or specialist physicians using DAA therapy.
DESIGN: Retrospective cohort study.
SETTING: Twelve urban, federally qualified health centers in the District of Columbia.
PARTICIPANTS: A total of 551 patients treated for HCV in the ASCEND investigation (A Phase IV Pilot Study to Assess of Community-based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection with HIV in the District of Columbia).
INTERVENTIONS: None.
MEASUREMENTS: Sustained viral response (SVR12), reinfection, retreatment, death.
RESULTS: In this large sample of majority Black individuals receiving care at community-based centers, there was an initial 87% rate of SVR, and after 5 years of follow up, an additional 6.5% of participants were found to be cured. This included individuals originally lost to follow up whose subsequent testing confirmed SVR12, and those with successful retreatment after initial treatment failure. There was a 70% rate of testing for reinfection, with 2 identified reinfections. Treatment outcomes were not associated with original treating provider type.
LIMITATIONS: As a retrospective analysis, these findings are limited by the availability of data in the electronic medical record.
CONCLUSIONS: DAA is an effective treatment for HCV and can safely be prescribed by multiple provider types, with favorable long-term outcomes.